Drew Moghanaki, Lung Cancer Specialist at UCLA Health Jonsson Cancer Center, shared a post on X:

“It’s reassuring to see longitudinal data aligning with the recommendations we provide patients with stage I NSCLC deciding between surgery and SBRT during usual care. As we say, ‘It’s a bumpier road in the beginning after surgery, yet patients have similar QOL a year later regardless of which upfront treatment they received.’ ”

Additional information.
Source: Drew Moghanaki/X